Is HAEMOGLOBIN DECREASED a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed HAEMOGLOBIN DECREASED.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 53 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported HAEMOGLOBIN DECREASED to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and HAEMOGLOBIN DECREASED. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause HAEMOGLOBIN DECREASED, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes HAEMOGLOBIN DECREASED. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if HAEMOGLOBIN DECREASED ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing HAEMOGLOBIN DECREASED: 53
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where HAEMOGLOBIN DECREASED is a reported side effect: 1.5921%

FDA reports of any drug causing HAEMOGLOBIN DECREASED : 37674
Average percentage for all medicated patients where HAEMOGLOBIN DECREASED is reported as a complication: 0.2361%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with HAEMOGLOBIN DECREASED:

ASPIRIN (4197 patients)
SOLIRIS (3009 patients)
LASIX (2026 patients)
ZOMETA (1960 patients)
FOLIC ACID (1726 patients)
PREDNISONE (1641 patients)
CLOZARIL (1629 patients)
REVLIMID (1608 patients)
OMEPRAZOLE (1480 patients)
EXJADE (1471 patients)
GLEEVEC (1435 patients)
FUROSEMIDE (1402 patients)
RIBAVIRIN (1397 patients)
WARFARIN SODIUM (1335 patients)
ACETAMINOPHEN (1279 patients)
ALLOPURINOL (1260 patients)
LIPITOR (1244 patients)
DEXAMETHASONE (1224 patients)
PREDNISOLONE (1190 patients)
COUMADIN (1168 patients)
SIMVASTATIN (1164 patients)
LISINOPRIL (1160 patients)
ARANESP (1151 patients)
PLAVIX (1151 patients)
FOSAMAX (1119 patients)
CISPLATIN (1021 patients)
REBETOL (1005 patients)
NORVASC (995 patients)
METHOTREXATE (992 patients)
PEGASYS (974 patients)
DECADRON (959 patients)
FLUOROURACIL (951 patients)
NEXIUM (942 patients)
CYCLOPHOSPHAMIDE (927 patients)
ATENOLOL (899 patients)
CARBOPLATIN (893 patients)
LEVOTHYROXINE SODIUM (889 patients)
PROCRIT (878 patients)
SYNTHROID (839 patients)
PEG-INTRON (827 patients)
LOVENOX (819 patients)
POTASSIUM CHLORIDE (799 patients)
PROTONIX (786 patients)
LANSOPRAZOLE (782 patients)
DIGOXIN (764 patients)
REMICADE (739 patients)
DIOVAN (735 patients)
VELCADE (734 patients)
AMLODIPINE (726 patients)
PRILOSEC (711 patients)
HYDROCHLOROTHIAZIDE (700 patients)
PREDNISONE TAB (685 patients)
IBUPROFEN (683 patients)
VIOXX (674 patients)
EPOGEN (657 patients)
ZOFRAN (647 patients)
LORAZEPAM (645 patients)
HUMIRA (633 patients)
METFORMIN HCL (628 patients)
HEPARIN (623 patients)
OXYCONTIN (621 patients)
METOPROLOL TARTRATE (603 patients)
RAMIPRIL (585 patients)
ALBUTEROL (573 patients)
FERROUS SULFATE TAB (572 patients)
ATIVAN (570 patients)
ZOCOR (556 patients)
XANAX (548 patients)
AMBIEN (546 patients)
COPEGUS (544 patients)
SANDOSTATIN LAR (542 patients)
MORPHINE (539 patients)
NEURONTIN (532 patients)
VITAMIN D (523 patients)
TOPROL-XL (522 patients)
AVASTIN (517 patients)
PREVACID (517 patients)
ACYCLOVIR (516 patients)
INSULIN (511 patients)
CYCLOSPORINE (507 patients)
PRADAXA (501 patients)
AREDIA (492 patients)
VOLTAREN (487 patients)
FAMOTIDINE (483 patients)
TAXOTERE (482 patients)
GABAPENTIN (482 patients)
COMPAZINE (477 patients)
VITAMIN B-12 (467 patients)
FLUCONAZOLE (467 patients)
CELEBREX (465 patients)
VICODIN (464 patients)
PERCOCET (461 patients)
SPIRONOLACTONE (457 patients)
CLOZAPINE (454 patients)
ZOLOFT (453 patients)
AFINITOR (445 patients)
ETOPOSIDE (441 patients)
BACTRIM (438 patients)
CYTARABINE (435 patients)
OXALIPLATIN (433 patients)
TELAVIC (TELAPREVIR) (427 patients)
IRON (425 patients)
LEVAQUIN (416 patients)
TAXOL (412 patients)
PAXIL (408 patients)
ARIXTRA (407 patients)
TRAMADOL HCL (406 patients)
OXYCODONE HCL (403 patients)
NEUPOGEN (401 patients)
ENOXAPARIN SODIUM (396 patients)
MYCOPHENOLATE MOFETIL (391 patients)
ENALAPRIL MALEATE (390 patients)
MULTI-VITAMINS (388 patients)
ZYPREXA (386 patients)
CLOPIDOGREL (384 patients)
LACTULOSE (384 patients)
CALCIUM (384 patients)
LEXAPRO (382 patients)
COREG (381 patients)
VANCOMYCIN (375 patients)
CIPROFLOXACIN (373 patients)
PACLITAXEL (371 patients)
ALDACTONE (370 patients)
DEXAMETHASONE TAB (368 patients)
RANITIDINE (368 patients)
LYRICA (366 patients)
LANTUS (361 patients)
METOCLOPRAMIDE (361 patients)
ENBREL (359 patients)
CARVEDILOL (359 patients)
MAGNESIUM OXIDE (359 patients)
VINCRISTINE (358 patients)
PANTOPRAZOLE SODIUM (356 patients)
CALCIUM CARBONATE (355 patients)
METOPROLOL (355 patients)
NEXAVAR (350 patients)
FENTANYL (348 patients)
NEORAL (347 patients)
COLACE (346 patients)
NITROGLYCERIN (345 patients)
BENADRYL (343 patients)
TRACLEER (341 patients)
GEMCITABINE (338 patients)
TEGRETOL (338 patients)
DIFLUCAN (335 patients)
MULTI-VITAMIN (334 patients)
GEMZAR (330 patients)
ADVAIR DISKUS 100/50 (330 patients)
FLOMAX (329 patients)
ZANTAC (327 patients)
DOXORUBICIN HCL (326 patients)
PANTOPRAZOLE (325 patients)
RITUXIMAB (325 patients)
SUTENT (325 patients)
AVONEX (322 patients)
MORPHINE SULFATE (322 patients)
PREDONINE (320 patients)
LOXONIN (319 patients)
CYMBALTA (318 patients)
FORTEO (316 patients)
KYTRIL (316 patients)
COZAAR (316 patients)
TASIGNA (314 patients)
CITALOPRAM HYDROBROMIDE (314 patients)
CLONAZEPAM (314 patients)
LEUCOVORIN CALCIUM (309 patients)
MUCOSTA (307 patients)
NAPROXEN (307 patients)
LOPRESSOR (306 patients)
BISOPROLOL FUMARATE (304 patients)
ACETYLSALICYLIC ACID SRT (304 patients)
SEROQUEL (304 patients)
TYLENOL (CAPLET) (304 patients)
AMLODIPINE BESYLATE (299 patients)
MIRCERA (293 patients)
TYLENOL (290 patients)
ATORVASTATIN CALCIUM (289 patients)
DILAUDID (287 patients)
ASCORBIC ACID (287 patients)
CRESTOR (284 patients)
RADIATION THERAPY (283 patients)
ACCUTANE (282 patients)
BEVACIZUMAB (280 patients)
THALOMID (280 patients)
SPIRIVA (279 patients)
METOPROLOL SUCCINATE (278 patients)
ALPRAZOLAM (276 patients)
DURAGESIC-100 (275 patients)
CAPECITABINE (273 patients)
PEPCID (272 patients)
PROGRAF (271 patients)
GLYBURIDE (270 patients)
VITAMIN E (270 patients)
DIAZEPAM (269 patients)
NYSTATIN (267 patients)
EFFEXOR (267 patients)
NEULASTA (264 patients)
CLONIDINE (262 patients)
LEVOFLOXACIN (262 patients)
GLIPIZIDE (262 patients)
ONDANSETRON (260 patients)
RAPAMUNE (260 patients)
CELLCEPT (259 patients)
ALENDRONATE SODIUM (259 patients)
TACROLIMUS (256 patients)
DICLOFENAC SODIUM (256 patients)
KEPPRA (255 patients)
VALTREX (246 patients)
ACTONEL (244 patients)
METHYLPREDNISOLONE (243 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about HAEMOGLOBIN DECREASED and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.